ADMA Biologics Inc (ADMA)

Current ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Total current assets	US$ in thousands	318,193	303,691	276,419	257,013	273,699	266,243	264,086	270,402	224,095	222,774	239,800	208,729	174,785	171,355	177,277	153,741	139,549	142,990	165,488	85,820
Total current liabilities	US$ in thousands	44,891	44,177	53,088	49,806	41,841	41,952	36,728	39,267	44,440	28,072	31,567	30,378	32,337	18,186	21,206	19,947	16,474	12,880	13,908	14,028
Current ratio		7.09	6.87	5.21	5.16	6.54	6.35	7.19	6.89	5.04	7.94	7.60	6.87	5.41	9.42	8.36	7.71	8.47	11.10	11.90	6.12

September 30, 2024 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $318,193K ÷ $44,891K
= 7.09

The current ratio of ADMA Biologics Inc has shown fluctuations over the past few quarters. It stood at 7.09 as of September 30, 2024, indicating that the company had $7.09 in current assets for every $1 of current liabilities. While this ratio is generally considered healthy, it is important to note the downward trend from the previous quarter's 6.87.

Looking at historical data, the current ratio has varied significantly, ranging from a low of 5.04 to a high of 11.90 over the past two years. This suggests fluctuations in the company's liquidity position and its ability to meet short-term obligations. It is essential for investors and stakeholders to monitor this ratio closely, as a sustained decline could indicate potential liquidity challenges for the company.

Overall, the current ratio of ADMA Biologics Inc has been relatively strong in recent quarters, but the downward trend raises some concerns about its short-term liquidity position. Further analysis of the company's current assets and liabilities composition would provide more insight into its liquidity management and financial health.